Developer docs
API playgroundTry for free, no card

Search company profiles

Weatherden

Full company profile

uuid000gtfr

Namestring
Weatherden
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Weatherden is a private, for-profit clinical development consulting group headquartered in London, United Kingdom, founded in 2017. The firm positions itself as serving clients in the clinical development lifecycle, a domain that typically encompasses translational planning, clinical trial design, regulatory strategy, and program execution support for biopharma and biotech sponsors. Its leadership comprises Emma Tinsley as Chief Executive Officer and Houman Ashrafian as Chairman of the Board, suggesting a senior-led consulting model rather than a technology-platform model.

The company's operating footprint is concentrated in London, with reported headcount in the 11–50 employee range, consistent with a boutique professional services firm. No detailed product, technology, pricing, or service-line disclosures are present in the supplied source material; the primary website (weatherden.co.uk) returned only a verification/loading page at the time of capture and contributed no additional operational detail. Consequently, the specific service mix, delivery model, and underlying tooling cannot be substantiated from the available data.

Based on the available evidence, Weatherden's business model appears to be fee-for-service consulting revenue from pharmaceutical, biotech, or academic clinical development clients, though no customer list, contract values, or revenue figures are disclosed. There is no public record of funding rounds, partnerships, awards, certifications, or M&A activity in the input. The investment-relevant takeaway is that Weatherden is a small, privately held UK clinical consulting boutique with limited publicly verifiable scale or differentiation data; further diligence on client base, utilization, and senior consultant bench would be required to substantiate any growth or valuation thesis.

Short descriptiontext

Weatherden is a London-based clinical development consulting group founded in 2017, serving biopharma and biotech clients with small-scale (11–50 employees) advisory support across the clinical development lifecycle.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
clinical development consulting, pharmaceutical consulting, drug development services, biotech advisory services, clinical trial strategy
NAICS code2 codes
  • Management Consulting Services54161
  • Other Scientific and Technical Consulting Services54169
SIC code2 codes
  • Services-Management Consulting Services8742
  • Services-Health Services8000
Product category
Pharmaceutical & Biotech Consulting
No data
Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Weatherden is a London-based clinical development consulting group that provides advisory and consulting services to pharmaceutical and biotechnology companies. The firm supports clients across drug development programs, helping navigate clinical strategy, trial design, and regulatory pathways. It operates as a specialized consultancy rather than a software or product vendor.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Clinical Development Consulting
CategoryPharmaceutical & Biotech Consulting
Description

Advisory and consulting services supporting pharmaceutical and biotechnology sponsors across clinical development strategy, trial design, and regulatory planning. Intended for drug development teams within pharma and biotech organizations.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

IQVIA is the world's largest CRO with deep clinical development consulting, real-world evidence, and technology-enabled development services. Comparable to Weatherden as the dominant end-to-end incumbent that increasingly absorbs boutique-style clinical advisory work into its R&D Solutions umbrella.

TypeBroad incumbent
Description

ICON plc is a global CRO with substantial clinical development consulting and strategic advisory services post-PRA Health Sciences. Comparable to Weatherden as a top-tier incumbent offering both operational trial delivery and clinical development advisory, often competing for the same biotech sponsor engagements.

TypeBroad incumbent
Description

Parexel is a large global CRO with deep clinical development consulting across biostatistics, regulatory, and clinical strategy. Comparable to Weatherden as a scaled incumbent whose consulting arms overlap directly with boutique specialists serving biotech and mid-cap pharma sponsors.

TypeBroad incumbent
Description

Medpace is a mid-to-large CRO with embedded medical and clinical development advisory focused on biotech and small-to-mid pharma. Comparable to Weatherden in sponsor segment focus and clinical development advisory depth, but operating at substantially larger scale.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-sized global CRO offering full-service clinical development plus scientific and regulatory consulting to biotech and pharma sponsors. Comparable to Weatherden as a more concentrated peer in clinical development advisory, with overlapping biotech sponsor focus and similar positioning between boutique and tier-1 CROs.

TypeDirect peer
Description

CTI Clinical Trial and Consulting Services is a privately held CRO combining clinical operations with biostatistics, regulatory, and consulting services, especially in rare disease and oncology. Comparable to Weatherden as a mid-sized peer operating clinical development consulting alongside operational delivery, more often to smaller biotech sponsors.

TypeBroad incumbent
Description

Charles River Laboratories is a large CRO/CDMO with a meaningful clinical development consulting offering alongside preclinical and manufacturing services. Comparable to Weatherden in the consulting function, though Charles River operates at significantly greater scale and breadth across the drug development value chain.

TypeBroad incumbent
Description

Syneos Health is a global biopharma solutions organization combining CRO and commercial services with embedded clinical development advisory. Comparable to Weatherden at the incumbent end of the clinical consulting market, frequently bidding against specialists for biotech development engagements.

TypeDirect peer
Description

Catalyst Clinical Research is an independent mid-sized CRO with specialty clinical development consulting across oncology, rare disease, and cell/gene therapy. Comparable to Weatherden as an independent peer with combined operational delivery and consulting, similar in size profile and biotech sponsor emphasis.

TypeDirect peer
Description

Precision Medicine Group is a specialty clinical development and biomarker services provider with embedded consulting across clinical strategy, biostatistics, and regulatory. Comparable to Weatherden as a focused clinical development services specialist serving biotech and emerging pharma, often competing for similar niche engagements.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Weatherden

Pharmaceutical & Biotech Consultingweatherden.co.uk

Weatherden is a London-based clinical development consulting group founded in 2017, serving biopharma and biotech clients with small-scale (11–50 employees) advisory support across the clinical development lifecycle.

What Weatherden does

Weatherden is a private, for-profit clinical development consulting group headquartered in London, United Kingdom, founded in 2017. The firm positions itself as serving clients in the clinical development lifecycle, a domain that typically encompasses translational planning, clinical trial design, regulatory strategy, and program execution support for biopharma and biotech sponsors. Its leadership comprises Emma Tinsley as Chief Executive Officer and Houman Ashrafian as Chairman of the Board, suggesting a senior-led consulting model rather than a technology-platform model.

The company's operating footprint is concentrated in London, with reported headcount in the 11–50 employee range, consistent with a boutique professional services firm. No detailed product, technology, pricing, or service-line disclosures are present in the supplied source material; the primary website (weatherden.co.uk) returned only a verification/loading page at the time of capture and contributed no additional operational detail. Consequently, the specific service mix, delivery model, and underlying tooling cannot be substantiated from the available data.

Based on the available evidence, Weatherden's business model appears to be fee-for-service consulting revenue from pharmaceutical, biotech, or academic clinical development clients, though no customer list, contract values, or revenue figures are disclosed. There is no public record of funding rounds, partnerships, awards, certifications, or M&A activity in the input. The investment-relevant takeaway is that Weatherden is a small, privately held UK clinical consulting boutique with limited publicly verifiable scale or differentiation data; further diligence on client base, utilization, and senior consultant bench would be required to substantiate any growth or valuation thesis.

Weatherden firmographics

Firmographics
Name
Weatherden
Website
https://weatherden.co.uk
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Weatherden is a London-based clinical development consulting group founded in 2017, serving biopharma and biotech clients with small-scale (11–50 employees) advisory support across the clinical development lifecycle.
Ownership category
akta.pro rank

Where Weatherden is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

Weatherden business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Weatherden product offering

Product offering

Core offering

Weatherden is a London-based clinical development consulting group that provides advisory and consulting services to pharmaceutical and biotechnology companies. The firm supports clients across drug development programs, helping navigate clinical strategy, trial design, and regulatory pathways. It operates as a specialized consultancy rather than a software or product vendor.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Development Consulting Advisory and consulting services supporting pharmaceutical and biotechnology sponsors across clinical development strategy, trial design, and regulatory planning. Intended for drug development teams within pharma and biotech organizations.

Companies that use Weatherden

Customer profile

Ideal customer profiles1 record

Weatherden technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Weatherden partnerships and signals

Strategic signal

Recent moves2 records

Expansion highlights1 record

Weatherden competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: IQVIA is the world's largest CRO with deep clinical development consulting, real-world evidence, and technology-enabled development services. Comparable to Weatherden as the dominant end-to-end incumbent that increasingly absorbs boutique-style clinical advisory work into its R&D Solutions umbrella.
  • ICON plc: ICON plc is a global CRO with substantial clinical development consulting and strategic advisory services post-PRA Health Sciences. Comparable to Weatherden as a top-tier incumbent offering both operational trial delivery and clinical development advisory, often competing for the same biotech sponsor engagements.
  • Parexel International: Parexel is a large global CRO with deep clinical development consulting across biostatistics, regulatory, and clinical strategy. Comparable to Weatherden as a scaled incumbent whose consulting arms overlap directly with boutique specialists serving biotech and mid-cap pharma sponsors.
  • Medpace: Medpace is a mid-to-large CRO with embedded medical and clinical development advisory focused on biotech and small-to-mid pharma. Comparable to Weatherden in sponsor segment focus and clinical development advisory depth, but operating at substantially larger scale.
  • Charles River Laboratories: Charles River Laboratories is a large CRO/CDMO with a meaningful clinical development consulting offering alongside preclinical and manufacturing services. Comparable to Weatherden in the consulting function, though Charles River operates at significantly greater scale and breadth across the drug development value chain.
  • Syneos Health (now part of Elliott/Veritas): Syneos Health is a global biopharma solutions organization combining CRO and commercial services with embedded clinical development advisory. Comparable to Weatherden at the incumbent end of the clinical consulting market, frequently bidding against specialists for biotech development engagements.

Direct peers

  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized global CRO offering full-service clinical development plus scientific and regulatory consulting to biotech and pharma sponsors. Comparable to Weatherden as a more concentrated peer in clinical development advisory, with overlapping biotech sponsor focus and similar positioning between boutique and tier-1 CROs.
  • CTI Clinical Trial and Consulting Services: CTI Clinical Trial and Consulting Services is a privately held CRO combining clinical operations with biostatistics, regulatory, and consulting services, especially in rare disease and oncology. Comparable to Weatherden as a mid-sized peer operating clinical development consulting alongside operational delivery, more often to smaller biotech sponsors.
  • Catalyst Clinical Research: Catalyst Clinical Research is an independent mid-sized CRO with specialty clinical development consulting across oncology, rare disease, and cell/gene therapy. Comparable to Weatherden as an independent peer with combined operational delivery and consulting, similar in size profile and biotech sponsor emphasis.
  • Precision Medicine Group: Precision Medicine Group is a specialty clinical development and biomarker services provider with embedded consulting across clinical strategy, biostatistics, and regulatory. Comparable to Weatherden as a focused clinical development services specialist serving biotech and emerging pharma, often competing for similar niche engagements.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Weatherden financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Weatherden leadership team

Management profile

Number of profiles

Profiles2 records

Weatherden funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Weatherden M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Weatherden

What does Weatherden do?

Weatherden is a London-based clinical development consulting group that provides advisory and consulting services to pharmaceutical and biotechnology companies. The firm supports clients across drug development programs, helping navigate clinical strategy, trial design, and regulatory pathways. It operates as a specialized consultancy rather than a software or product vendor.

When was Weatherden founded?

Weatherden was founded in 2017. It employs 11 to 50 people.

Where is Weatherden based?

Weatherden is headquartered in London, United Kingdom, in the Europe region.

Who are Weatherden's main competitors?

Broad incumbents on record are IQVIA, ICON plc, Parexel International, Medpace, Charles River Laboratories and Syneos Health (now part of Elliott/Veritas). Direct peers are Worldwide Clinical Trials, CTI Clinical Trial and Consulting Services, Catalyst Clinical Research and Precision Medicine Group.

Does Weatherden have an API?

No public API is recorded for Weatherden.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceElevara Medicines Appoints Biotech Veteran as CEOElevara Medicines appointed Mai-Britt Zocca as CEO effective 1 July 2026, succeeding founder Emma Tinsley, who will become a non-executive director. Zocca previously led IO Biotech, and the company's $70 million Series A funds its Phase 2b trial of ELV001 for rheumatoid arthritis.FierceBiotechBritish biotech emerges with $70M series A and midstage arthritis assetBritish biotech Elevara Medicines has emerged from stealth with a $70 million series A round to advance its phase 2-ready oral CDK4/6 inhibitor ELV001 for rheumatoid arthritis, with plans to launch a trial enrolling around 180 patients by year-end. The company licensed exclusive global rights to ELV001 from Japanese pharma company Teijin Pharma, with the funding round led by Forbion and Sofinnova Partners alongside Monograph Capital and founder Weatherden. Elevara will also use the proceeds to explore programs in other chronic inflammatory conditions and women's health.BioSpaceSosei Heptares to Embed Agile Operating Model and Enhance its Translational Medicine Capabilities through Strategic Collaboration with WeatherdenSosei Heptares announced a strategic collaboration with Weatherden to accelerate its pipeline programs through Phase 1b/2a trials to clinical proof-of-concept. The partnership aims to embed an agile operating model and enhance translational medicine capabilities, with no change to FY2022 R&D expense guidance.GlobeNewswireSosei Heptares to Embed Agile Operating Model and Enhance its Translational Medicine Capabilities through Strategic Collaboration with WeatherdenSosei Heptares announced a strategic collaboration with Weatherden to build an agile operating model and enhance its translational medicine capabilities. The partnership aims to accelerate pipeline programs through Phase 1b/2a trials to clinical proof-of-concept, with no change to FY2022 R&D expense guidance.WeatherdenCase studies — WeatherdenWeatherden presents a portfolio of case studies detailing its consulting services for biopharmaceutical and biotech clients, including clinical strategy design, regulatory submissions, and company formation. The article highlights specific engagements such as securing FDA priority review vouchers, obtaining EMA orphan designations, and developing novel trial protocols accepted by major regulators. It further notes the firm's track record of advising over 200 companies and managing trials across multiple international locations.